ipilimumab,lenalidomide,tafasitamab,mor00208
bms,morphosys,incyte
['dlbcl', 'l-mind', ' ipi ']
rw outcomes with tafa-len in r/r dlbcl. % of transformed and hgbcl, ipi and advanced stage than in l-mind, 50% primary refract, 38%&gt; 2 lines. disappointing outcomes in this unselected population, more similar to the ones in our practice. #ash22 
hematologa en Fleming, lymphoma fan, mama de Luchi, un poco yogi y mucha acuarela!